Agoracom Blog Home

Posts Tagged ‘Healthcare’

Predictiv AI’s $PAI.ca $INOTF ThermalPass Adopted by Memorial Healthcare System $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 9:45 AM on Friday, April 9th, 2021
Predictiv AI

TORONTO , April 9, 2021 – Predictiv AI Inc. TSXV: PAI) (OTC: INOTF) (FSE: 71TA ) (” Predictiv AI ” or the ” Company “), www.predictiv.ai , a software and solutions provider in the artificial intelligence markets, is pleased to announce it has installed multiple ThermalPass temperature scanning devices in Memorial Healthcare System hospital facilities in south Broward County.

Memorial is a leader in providing high-quality healthcare services to South Florida residents through its six-hospital network and various ancillaries throughout South Florida.  The initial rollout of units was completed at Memorial Regional Hospital, the flagship facility and one of the largest hospitals in the state and Memorial Regional Hospital South, home of the Rehabilitation Institute.

“With COVID-19 still threatening our community, it’s important for us to continue using technology in a way that will help us maximize our team’s time and provide quality and safe care to our community,” said Dawn de la Vega , MSN, RN, Director of Nursing at Memorial Regional Hospital.  “We have integrated ThermalPass, which has helped us eliminate forehead temperature checks and capture core temperature for employees reporting to work in a more efficient manner.”

“It is an honour to be of service to one of America’s top healthcare systems, having garnered many prestigious awards over the years, including having been selected by the American Hospital Association from more than 5,000 hospitals as the national model for improving the health of the community,” said Jason Elmaleh, President of Commersive Solutions, joint venture partner in ThermalPass.

Read More: https://agoracom.com/ir/PredictivAI/forums/discussion/topics/758783-predictiv-ai-s-thermalpass-adopted-by-memorial-healthcare-system/messages/2311375#message

Predictiv AI’s $PAI.ca $INOTF Weather Telematics Partners with Propel IT to Accelerate Commercialization of IT SaaS Fleet Safety Platform $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 9:45 AM on Tuesday, March 23rd, 2021
Predictiv AI

TORONTO , March 23, 2021 /PRNewswire/ – Predictiv AI Inc. (TSXV: PAI) (OTC: INOTF) (FSE: 71TA) (” Predictiv AI ” or the ” Company “), www.predictiv.ai , a software and solutions provider in the artificial intelligence markets is pleased to announce that its wholly-owned subsidiary, Weather Telematics Inc. (” WTX “), has formalized a strategic product integration partnership with Propel IT Inc. (” Propel “).

The new partnership will significantly enhance available real-time data to which drivers and dispatchers can access. WTX’s hyperlocal, advanced road weather hazard alert system warns drivers of impending dangerous conditions such as black ice, poor visibility and hydroplaning.

Propel is a technology and data company that maximizes safety and efficiency in commercial fleets, who have been serving the transportation and logistics industry in the United States for more than 9 years. Propel is focused on improving driver safety, lowering insurance costs, and reducing environmental impact through fuel savings. Once commercially deployed and integrated, the Alert Fleet system will run as a SAAS model with a monthly recurring revenue component proportionate to the number of vehicles within a customer’s fleet.

“Smarter driving to us means preventing and reducing the impact of accidents for drivers and others on the road. By integrating Alert Fleet with our existing software offerings, our users will now have access to unparalleled real-time advanced hazardous road condition alerts which greatly enhances our efforts to save lives and minimize accidents that could otherwise have been preventable,” said Michael Dieschbourg, President of Propel IT.”

Read More: https://agoracom.com/ir/PredictivAI/forums/discussion/topics/757865-predictiv-ai-s-weather-telematics-partners-with-propel-it-to-accelerate-commercialization-of-it-saas-fleet-safety-platform/messages/2309368#message

Waterloo.AI and AMC: #AI Industry Day – Webinar Event on March 25, 2021 | 8:30 am to 4:00 pm – Predictiv AI $PAI.ca $INOTF $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 6:57 PM on Saturday, March 20th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/02/PAI-Square1.jpg

Earlier this week, Predictiv AI announced a new partnership with the Waterloo Artificial Intelligence Institute at the University of Waterloo. The collaboration will allow Predictiv AI’s subsidiary, AI Labs Inc., access to the world’s top artificial intelligence resources, creating much greater bandwidth in ideation, research, and development of solutions for real-world problems.

“We are very excited and honoured to be working with one of the world’s leading artificial intelligence institutions. We will now be able to accelerate our innovations and scale our team’s productivity while learning new ways to approach projects with new and unique technologies,” said Michael Lende, CEO of Predictiv AI. “The formalization of this relationship is a crucial building block in our growth plans as it allows us to remain asset-light while simultaneously accelerating innovation on our artificial intelligence and deep machine learning-based solutions. We look forward to a long-term association with Waterloo.AI.”

As part of our ongoing efforts to support Waterloo.AI and its partners, we’re very pleased to share information about an event they will be hosting next week – AI Industry Day on Tuesday, March 25th

The event will be hosted via Microsoft Teams and will be an interactive and informative online event, enabling Industry to get more acquainted with various AI success stories across multi-sectors of the economy. Catering to diverse interests, attendees will have the option to choose from a menu of topics, with one stream focusing on the use of AI within Advanced Manufacturing. Applicable to all sectors, the keynote speaker will deliver the first-hand experience of “The Journey to Implement AI”, and the importance of “Data” in the future of AI. Morning and afternoon presentations are planned around a mid- day networking event amongst attendees, partners, researchers, and the Waterloo AI Eco-System.

Please feel free to check out the agenda below, click the previous link to discover more information about the event and/or additional details about each presentation, and lastly, make sure to register for the event

– it’s completely free and promises to be fun & informative!

Click image to enlarge.

XPhyto Therapeutics $XPHY.ca $XPHYF Announces European Approval for 25 Minute COVID-19 PCR Test $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:35 AM on Thursday, March 18th, 2021
This image has an empty alt attribute; its file name is XPHYTO-70-x-70.jpg
  • CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2
  • Rapid results with ease of use – single 20-minute PCR cycle plus 5-minute detection process
  • High sensitivity – 104.73 c/PCR limit of detection with 95% confidence interval
  • High specificity – zero cross-reactivity on 19x respiratory infectious disease panel
  • High robustness – no impact on results from minor changes in process parameters
  • 100% repeatability and laboratory precision observed
  • Sales launch in Europe planned for April 2021

XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.

“Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” said Hugh Rogers, CEO and Director of XPhyto. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”

Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. For assay performance, Covid-ID Lab requires only a single 20-minute PCR thermal cycle without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces the risk of cross-contamination and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.

During validation of the assay, the limit of detection for SARS-CoV-2 RNA was determined to be 104.73 c/PCR within a 95% confidence interval. Specificity of 100% against 19 other pathogens of serious respiratory infections was demonstrated on a respiratory verification panel. Precision was determined through evaluation of variance of the analysis results due to random deviations, a repeatability/intra-assay precision evaluation (same lab, user, equipment, etc.), and a laboratory precision evaluation (different lab, user, equipment, etc.). Robustness was measured by evaluation of the impact of minor changes on process parameters (transport medium, PCR cycler model, ramp rate, template volume, hybridization mixing ratio, etc.). The validation studies were carried out accordingly to ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology and VQ-015 Validation of Methods, European Medicines Agency. The quality management system was in accordance with EN ISO 13485: 2016 and EN ISO 9001: 2015.

Read More:https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/757566-xphyto-announces-european-approval-for-25-minute-covid-19-pcr-test/messages/2308737#message

Predictiv AI $PAI.ca $INOTF Partners With Waterloo Artificial Intelligence Institute at University of Waterloo

Posted by AGORACOM at 10:36 AM on Tuesday, March 16th, 2021
Predictiv AI

TORONTO , March 16, 2021 /PRNewswire/ – Predictiv AI Inc. (TSXV: PAI) (OTC: INOTF) (FSE: 71TA) (” Predictiv AI ” or the ” Company “), a software and solutions provider in the artificial intelligence markets is pleased to announce its dynamic new partnership with the Waterloo Artificial Intelligence Institute (“Waterloo.AI”) at the University of Waterloo . This partnership will allow Predictiv AI’s subsidiary, AI Labs Inc. (“AI Labs”), to pursue its various innovations through leveraging Waterloo.AI as an extension of the Predictiv AI team.

Predictiv AI Inc. (CNW Group/Predictiv AI Inc.)

The collaboration will allow access to the world’s top artificial intelligence resources, creating much greater bandwidth in ideation, research, and development of solutions for real-world problems. Predictiv AI also looks forward to participating in and supporting Waterloo.AI events and introducing other synergistic partners to the program. Beyond having access to an unparalleled talent pool of academics and their teams for research and development, the partnership also provides for round table participation amongst Waterloo.AI partners.

“We are thrilled to have Predictiv AI join as a partner with Waterloo,” said Harold Godwin , Managing Director of Waterloo.AI. “This is a very exciting time for our university and Waterloo.AI, and we are grateful for the interest and ongoing support of our partners, including our newest, Predictiv AI.”

“We are very excited and honoured to be working with one of the world’s leading artificial intelligence institutions. We will now be able to accelerate our innovations and scale our team’s productivity while learning new ways to approach projects with new and unique technologies,” said Michael Lende, CEO of Predictiv AI.

Read More: https://agoracom.com/ir/PredictivAI/forums/discussion/topics/757422-predictiv-ai-partners-with-waterloo-artificial-intelligence-institute-at-university-of-waterloo/messages/2308360#message

XPhyto Therapeutics $XPHY.ca $XPHYF Completes Corporate Rebranding and Launches New Website $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:05 AM on Thursday, March 4th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/01/XPHYTO-70-x-70.jpg
  • Rebranding Reflects XPhyto’s Commitment To Operational Achievement
  • Product Development Advance From The Lab To The Clinic
  • Cusp Of Two Major Commercial Milestones Related To Our Rapid Point-Of-Care COVID-19 PCR Test System
  • A Bioscience Accelerator At The Leading-Edge Of The Life Science Industry

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at www.xphyto.com.

The rebranding decision reflects the Company’s commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting value creation through commercialization of its development pipeline and focused investment in impact driven innovation.

“The Company is excited to introduce a fresh look at such a pivotal point in our business growth,” said Hugh Rogers, CEO & Director of XPhyto. “With all technical requirements fulfilled, we are on the cusp of two major commercial milestones related to our rapid point-of-care COVID-19 PCR test system. With expected ISO certification and CE-IVD approval pending, we are excited to enter the next phase of our business with a positive, crisp and energetic new image.”

The Company will provide further information and updates in due course. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. Further, its COVID-19 related test products are not yet approved and are still subject to risks associated with the regulatory approval process.

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/756560-xphyto-completes-corporate-rebranding-and-launches-new-website/messages/2306460#message

XPhyto Therapeutics $XPHY.ca $XPHYF Places First Order for 25-Minute Covid-19 RT-PCR Tests $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:05 AM on Wednesday, February 24th, 2021
This image has an empty alt attribute; its file name is XPHYTO-70-x-70.jpg
  • Placed First Order for its Rapid Point-Of-Care COVID-19 Test System
  • 9600 Individual Tests Ordered
  • Mid-March Delivery
  • Additional Pandemic-Focused Biosensors in Development

XPhyto Therapeutics. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that it has placed the first order for its rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”) from its exclusive diagnostic development partner, 3a-diagnostics GmbH (“3a”).

The first order of Covid-ID Lab is for 9,600 individual tests, which are packaged in 200 kits of 48 tests each. Delivery of the first order is expected by mid-March 2021 and will be primarily used to supply prospective distribution partners and licensees and their respective government regulators with test samples for review and evaluation. The tests will be manufactured in the German state of Baden-Württemberg.

“We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,” said Hugh Rogers, CEO, and Director of XPhyto. “Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.”

Covid-ID Lab was designed to be a rapid, accurate, and robust COVID-19 test system with reduced operating costs and increased convenience and portability. XPhyto expects 3a to receive ISO 13485 medical device manufacturer approval by the end of February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March. Initial commercial manufacturing is planned for Germany, with additional capacity in other jurisdictions to follow. The sales launch in Europe is targeted for April 2021. XPhyto is currently in discussions with potential distribution and wholesale partners in Europe and the Middle East.

XPhyto and 3a are also developing a portfolio of oral biosensor screening tests for detection of bacterial and viral infectious diseases, including influenza A, group A strep, stomatitis, periimplantitis, and periodontitis. Additional pandemic-focused biosensors are in development, specifically for H1N1 (swine flu) and H5N1 (avian flu). The Company is planning the commercial launch of its first biosensor product in the second half of 2021.

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/755962-xphyto-places-first-order-for-25-minute-covid-19-rt-pcr-tests/messages/2305102#message

XPhyto Therapeutics $XPHY.ca $XPHYF Builds Commercial Team to Launch 25-Minute Covid-19 Test $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:32 AM on Monday, February 22nd, 2021
  • Expedited formation of commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system
  • Expects medical device manufacturer approval by the end of February
  • European regulatory approval as a commercial in vitro diagnostic device by early March.

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that the Company has expedited the formation of an experienced commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). XPhyto expects 3a to receive ISO 13485 medical device manufacturer approval by the end of February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March.

The market launch team consists of world-class clinical and pharmaceutical executives and service providers who bring the experience and expertise necessary to effectively and rapidly drive the commercialization of Covid-ID Lab. Collectively, the team brings decades of experience in the biotech and pharmaceutical industries, including: executive leadership, business development, regulatory compliance, product launch, international marketing and sales, production, quality assurance, and M&A. In particular, members of the team have led medical diagnostic company growth from inception to over 500 million Euro per year in multinational sales.

“We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization. The team has extensive experience from regulatory approval to international production and sales,” said Hugh Rogers, CEO and Director of XPhyto. “As we near expected regulatory approval, XPhyto’s business is rapidly evolving from innovation to impact. We are working hard to put the Company in the best possible position to execute on our business strategy.”

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/755782-xphyto-builds-commercial-team-to-launch-25-minute-covid-19-rt-pcr-test/messages/2304693#message

Predictiv AI $PAI.ca $INOTF Signs SISCO to Distribute Thermalpass to Its U.S. Customer Base

Posted by AGORACOM at 9:54 AM on Friday, February 19th, 2021
  • $PAI.ca’s ThermalPass will be paired with the SISCO Fast-Pass® Visitor Management System
  • The paired tech will assist with track-and-trace efforts and provide peace of mind to building occupants and visitors

TORONTO , Feb. 19, 2021 – Predictiv AI Inc. (TSX-V: PAI) (OTC: INOTF) (FSE: 71TA) (” Predictiv AI ” or the ” Company “), www.predictiv.ai , a software and solutions provider in the artificial intelligence markets is pleased to announce that Security Identification Systems Corp. (SISCO) www.siscocorp.com , has joined ThermalPass as a channel reseller and distributor to market and sell the ThermalPass to its U.S. customers in hospitality, healthcare, commercial enterprises and government.

ThermalPass will be paired with the SISCO Fast-Pass® Visitor Management System to assist with track-and-trace efforts and to provide enhanced peace of mind to building occupants and visitors.

Since 1994, SISCO has been dedicated to developing best-in-class visitor management solutions for confirming credentials and tracking people for public and private entities. Fully-compliant with the various legislation throughout the United States , SISCO provides world-class security products and services using state-of-the-art technologies and integrated security solutions.

“The seamless integration of ThermalPass’ technology allows us to immediately offer the new solution to all of our existing clients including Royal Caribbean International, Norwegian Cruise Line, Princess Cruises, Shriners International, Cleveland Clinic, HCA Healthcare, NYPD, Palm Beach Police Department, Miami Police Department, PPG Industries, J.W. Marriott, and many others,” said SISCO CEO Anthony Zagami.

“Because ThermalPass is a touchless screening device that operates much like a metal detector, taking multiple temperature readings instantaneously, when coupled with Fast-Pass, it immediately provides front-line workers with the necessary data and insight in handling high volumes of people entering facilities. This allows practitioners to respond accordingly with their organization’s standard operating procedures, and in real time.”

Read More: https://agoracom.com/ir/PredictivAI/forums/discussion/topics/755653-predictiv-ai-signs-sisco-to-distribute-thermalpass-to-its-u-s-customer-base/messages/2304352#message

Xphyto $XPHY.ca $XPHYF European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:11 AM on Tuesday, February 16th, 2021
  • Expects approval as a medical device manufacturer by late February
  • European regulatory approval as a commercial in vitro diagnostic device by early March.
  • Covid-ID Lab was designed to be a rapid, accurate and robust test system with reduced operating costs and increased convenience and portability.

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”), are pleased to announce all actions and procedures required for XPhyto Therapeutics Corp.’s European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system have been completed. 3a-diagnostics GmbH, Xphyto’s exclusive German diagnostics development partner, expects ISO 13485 approval as a medical device manufacturer by late February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March.

“We are very pleased with the team’s swift development progress,” said Hugh Rogers, CEO & Director of XPhyto. “Our goal was to create the fastest and most portable COVID-19 PCR test on the market. We are confident in our prospects for an expedited approval and look forward to commercial launch in short order”

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/755390-xphyto-european-ce-ivd-application-for-25-minute-covid-19-rt-pcr-test/messages/2303789#message